Sitavig

Chickenpox, Encephalitis, Herpes Simplex, Neutropenia + 18 more

Treatment

20 Active Studies for Sitavig

What is Sitavig

Acyclovir

The Generic name of this drug

Treatment Summary

Acyclovir is an antiviral drug used to treat different types of herpes, including herpes simplex, Varicella zoster, herpes zoster, herpes labialis, and acute herpetic keratitis. It is often the first treatment prescribed for these viruses and can be given to children as young as 6 years old. Acyclovir was approved by the FDA in 1982.

Zovirax

is the brand name

image of different drug pills on a surface

Sitavig Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zovirax

Acyclovir

1982

496

Effectiveness

How Sitavig Affects Patients

Acyclovir is a drug that stops the spread of viruses associated with herpes, such as cold sores. It works by blocking the DNA replication of the virus. Acyclovir is usually safe to take, even in large doses, and so it has a wide range of doses it can be taken at.

How Sitavig works in the body

Acyclovir works by interfering with the virus's ability to reproduce. When a virus infects a cell, it uses an enzyme called thymidine kinase to turn acyclovir into a form called acyclovir monophosphate. This form is then converted to a diphosphate form by guanylate kinase. The diphosphate form is then converted to the active form, acyclovir triphosphate, by enzymes like pyruvate kinase. Acyclovir triphosphate has a high affinity for the virus's DNA polymerase, and

When to interrupt dosage

The prescribed dosage of Sitavig is contingent upon the diagnosed condition, including Cytomegalovirus Infections, grave Genital herpes and Herpes simplex type I resurgence. The measure of dosage is contingent on the technique of delivery (e.g. Cream - Topical or Injection, powder, lyophilized, for solution - Intravenous) as detailed in the table below.

Condition

Dosage

Administration

Bone Marrow Transplant

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

Neutropenia

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

Genital Herpes

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

Herpes Simplex Infections

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

VZV re-activation

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

Chickenpox

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

Communicable Diseases

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

Immunocompromised

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

Herpes Genitalis

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

Shingles

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

Keratitis, Herpetic

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

Cytomegalovirus Infections

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

prophylaxis of VZV re-activation

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

Herpes Labialis

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

Genital Herpes

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

Herpes Simplex

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

Herpes Labialis

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

Bell Palsy

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

Encephalitis, Herpes Simplex

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

prophylaxis of HSV re-activation

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Cream - Topical, Cream, Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Intravenous, Powder, for solution - Intravenous, Ointment - Ophthalmic, Tablet - Buccal, Kit - Oral; Topical, Kit, Oral; Topical, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ophthalmic, Cutaneous, Ointment - Cutaneous

Warnings

Sitavig has one contraindication, thus it should not be blended with the ailments enumerated in the following table.

Sitavig Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Acyclovir may interact with Pulse Frequency

There are 20 known major drug interactions with Sitavig.

Common Sitavig Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The excretion of Abemaciclib can be decreased when combined with Acyclovir.

Neomycin

Major

The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Neomycin.

Procainamide

Major

The excretion of Procainamide can be decreased when combined with Acyclovir.

Tenofovir

Major

Acyclovir may increase the nephrotoxic activities of Tenofovir.

Tenofovir alafenamide

Major

Acyclovir may increase the nephrotoxic activities of Tenofovir alafenamide.

Sitavig Toxicity & Overdose Risk

Overdosing on Cyclosporin can cause agitation, loss of consciousness, seizures, and excessive sleepiness. These effects are more likely to occur in those who have not been monitored for fluid levels or kidney function. Treatment for Cyclosporin overdose should involve supportive care and addressing the symptoms.

image of a doctor in a lab doing drug, clinical research

Sitavig Novel Uses: Which Conditions Have a Clinical Trial Featuring Sitavig?

34 clinical studies are presently assessing the potential of Sitavig to prophylactically inhibit Varicella Zoster Virus (VZV) reactivation and reduce the incidence of Immunocompromised and Communicable Diseases.

Condition

Clinical Trials

Trial Phases

Encephalitis, Herpes Simplex

0 Actively Recruiting

Herpes Simplex Infections

0 Actively Recruiting

Herpes Genitalis

0 Actively Recruiting

VZV re-activation

0 Actively Recruiting

Chickenpox

3 Actively Recruiting

Phase 3

Neutropenia

4 Actively Recruiting

Phase 1, Phase 2, Phase 3

Cytomegalovirus Infections

0 Actively Recruiting

Genital Herpes

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Bone Marrow Transplant

30 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 1

Immunocompromised

2 Actively Recruiting

Phase 1, Not Applicable

Keratitis, Herpetic

0 Actively Recruiting

prophylaxis of HSV re-activation

0 Actively Recruiting

Shingles

3 Actively Recruiting

Phase 2, Phase 1

Herpes Simplex

0 Actively Recruiting

Herpes Labialis

0 Actively Recruiting

Genital Herpes

0 Actively Recruiting

prophylaxis of VZV re-activation

0 Actively Recruiting

Bell Palsy

0 Actively Recruiting

Herpes Labialis

0 Actively Recruiting

Sitavig Reviews: What are patients saying about Sitavig?

4.7

Patient Review

7/21/2020

Sitavig for Cold Sore

This drug is on the pricey side, but it cleared my cold sore quickly and I haven't had one in over 18 months.

1.7

Patient Review

2/10/2015

Sitavig for Cold Sore

Valtrex was more effective for me when taken at the first sign of a cold sore.

1

Patient Review

6/7/2016

Sitavig for Cold Sore

This pill is way too expensive for how ineffective it is. I had to keep taking oral pills even after starting this treatment, and I tried it twice just to give it a chance. No dice.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about sitavig

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How much does Sitavig cost?

"The average retail price of Sitavig is $1,202.11, 23% off the average retail price of $1,202.11. Compare herpes virus nucleosides."

Answered by AI

How long does it take for Sitavig to dissolve?

"When the tablet is applied to the gums, it needs to stay there for 6 hours, but it may take up to 14 hours to dissolve."

Answered by AI

What is Sitavig used for?

"SITAVIG is a prescription medicine that is used to treat cold sores in adults who have normal immune systems."

Answered by AI

Is Sitavig covered by insurance?

"Your doctor can prescribe a drug called Sitavig. The cost of the drug depends on your insurance coverage, any prescription deductibles you have, and your prescription copay. There is a patient access card for Sitavig which may reduce the copay for qualifying patients."

Answered by AI

Clinical Trials for Sitavig

Have you considered Sitavig clinical trials?

We made a collection of clinical trials featuring Sitavig, we think they might fit your search criteria.
Go to Trials
Image of University of Kansas Cancer Center in Kansas City, United States.

High Intensity Interval Training for Bone Marrow Transplant

18 - 80
All Sexes
Kansas City, KS

The goal of this clinical trial is to learn how a remotely monitored high-intensity interval training (REMM-HIIT) affects the cardiorespiratory fitness and physical function for patients planning to undergo stem cell transplantation. The main questions it aims to answer are: Is there a change in the participant's cardiorespiratory fitness level? Is there a change in the participant's physical function? Researchers will compare the REMM-HIIT program to a control group of participants who do not take part in the training program to see if REMM-HIIT helps improve stem cell transplantation outcomes. Participants will: * Complete cardiopulmonary exercise testing (CPET) 4 times during the study * Do basic tests to measure physical function 6 times during the study * Answer questions about their life and how they are feeling 6 times during the study * Wear a device to keep track of step counts and heart rate daily * Keep a log of every time they exercise throughout the study * Optionally, provide blood and stool samples 6 times during the study

Waitlist Available
Has No Placebo

University of Kansas Cancer Center (+2 Sites)

Anthony Sung, MD

Image of Weill Cornell Medical College in New York, United States.

Luspatercept for Clonal Cytopenia

18+
All Sexes
New York, NY

The purpose of this clinical trial is to test how well the drug luspatercept works in improving low blood cell counts in people with clonal cytopenias of uncertain significance (CCUS). The main questions the study seeks to answer include: * How many patients experience improvements in their low blood counts (red cells, platelets, or white cells) within 24 weeks, based on specific criteria for blood conditions like myelodysplastic syndromes (MDS)? * How long these improvements last before the condition worsens or changes. * The percentage of participants showing improvements at 12, 24, and 48 weeks. * How long it takes for the condition to progress to more severe diseases like myeloid disorders. * How long red blood cell responses last and how quickly these responses are seen. * The average change in hemoglobin levels over 24 weeks. * How many patients need blood transfusions during the study and how soon transfusions are required. * Changes in participants' well-being and energy levels based on a standardized questionnaire. * Monitoring for any side effects, including progression to MDS or leukemia, heart-related issues, or sudden increases in hemoglobin. Participants will: * Receive luspatercept as an injection every three weeks. * Visit the clinic every three weeks for treatment and monitoring.

Phase 2
Recruiting

Weill Cornell Medical College

Pinkal Desai, MD

Bristol-Myers Squibb

Have you considered Sitavig clinical trials?

We made a collection of clinical trials featuring Sitavig, we think they might fit your search criteria.
Go to Trials

Have you considered Sitavig clinical trials?

We made a collection of clinical trials featuring Sitavig, we think they might fit your search criteria.
Go to Trials